Price T Rowe Associates Inc Acadia Pharmaceuticals Inc Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,999,550 shares of ACAD stock, worth $62.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,999,550
Previous 5,178,509
22.77%
Holding current value
$62.4 Million
Previous $162 Million
54.39%
% of portfolio
0.01%
Previous 0.02%
Shares
14 transactions
Others Institutions Holding ACAD
# of Institutions
299Shares Held
158MCall Options Held
1.88MPut Options Held
688K-
Baker Bros. Advisors LP New York, NY42.9MShares$669 Million10.04% of portfolio
-
Rtw Investments, LP New York, NY13.8MShares$216 Million4.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$207 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$182 Million0.01% of portfolio
-
State Street Corp Boston, MA6MShares$93.6 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.52B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...